Table 2 Clinical and microbiological outcome and mortality in patients receiving systemic or systemic + inhaled colistin therapy
PE colistin | PE and inh. colistin | p | |
|---|---|---|---|
n (%) | n (%) | ||
Clinical outcome | |||
Clinical success | 30 (37.5) | 16 (37.2) | 0.974 |
Partial clinical improvement | 15 (18.8) | 1 (2.3) | 0.009 |
Clinical failure | 33 (41.3) | 22 (51.2) | 0.291 |
Recurrence | 2 (2.5) | 4 (9.3) | 0.094 |
Microbiological outcome | |||
Eradication | 40 (50) | 20 (46.5) | 0.712 |
Persistence | 30 (37.5) | 19 (44.2) | 0.470 |
Recurrence | 4 (5) | 4 (9.3) | 0.356 |
Colonization | 6 (7.5) | 0 (0) | 0.062 |
Mortality | 38 (47.5) | 23 (53.5) | 0.526 |
Side effects | |||
Nephrotoxicity | 43 (53.8) | 21 (48.8) | 0.603 |
Neurotoxicty | 0 | 0 | |
Local side effects | 0 | 0 | |